Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: The Eastern Cooperative Oncology Group experience

Seminars in Oncology

Volumn 21, Issue 5 SUPPL. 8, 1994, Pages 15-18

  Sledge Jr , G W ^a   Robert, N ^a   Sparano, J A ^a   Cobeligh, M ^a   Goldstein, L J ^a   Neuberg, D ^a   Rowinsky, E ^a   Baughman, C ^a   McCaskill Stevens, W ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ADVANCED CANCER; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CROSSOVER PROCEDURE; DOSE RESPONSE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS; DOXORUBICIN; HUMAN; NEOPLASM METASTASIS; PACLITAXEL; PROSPECTIVE STUDIES;

EID: 0028051587     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (0)